-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND SUPPLEMENTAL INFORMATION IN RELATION TO THE 2022 ANNUAL REPORT2023-08-31
-
DATE OF BOARD MEETING2023-08-21
-
VOLUNTARY ANNOUNCEMENT - COLLABORATION AGREEMENT WITH ANTENGENE2023-08-11
-
VOLUNTARY ANNOUNCEMENT - REGAINING OF THE RESEARCH, DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION RIGHTS TO ALMONERTINIB OUTSIDE OF THE PRC2023-08-04
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 20232023-08-02
-
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF "IBREXAFUNGERP TABLETS" ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2023-07-20
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 20232023-07-05
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "PEGMOLESATIDE INJECTION"2023-06-30
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME2023-06-30
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL NOTICE OF "HS-10518 CAPSULES"2023-06-29
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF“DAPAGLIFLOZIN TABLETS”2023-06-28
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL NOTICE OF “HS-10516 CAPSULES”2023-06-13